← ANALYST RATINGS · TIPRANKS
Jade Biosciences (JBIO): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $50.50, the highest $77.00, the lowest $40.00. The average is +274.9% from the last price of $13.47.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $47.00 | Buy | +248.9% | Reiterated | 15.10.26on TipRanks Oct 16 07:30 | +2.1%next day −1.0% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $47.00 | Buy | +248.9% | Reiterated | 01.10.26on TipRanks 08:50 | −2.2%next day +1.8% · 5 days +1.5% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $55.00 | Buy | +308.3% | Reiterated | 01.10.26on TipRanks 06:15 | −2.2%next day +1.8% · 5 days +1.5% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 30.09.26on TipRanks 14:15 | −0.7%next day −2.2% · 5 days −3.9% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $42.00 | Buy | +211.8% | Reiterated | 30.09.26on TipRanks 13:05 | −0.7%next day −2.2% · 5 days −3.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $15.00 → $14.50−3.3% | Hold | +7.6% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $14.50 → $13.50−6.9% | Sell | +0.2% | Downgrade | 30.09.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.50 → $14.00−3.4% | Hold | +3.9% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.50 → $14.00−3.4% | Hold | +3.9% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.50 | Hold | +7.6% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $14.00 | Hold | +3.9% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $25.00 → $48.00+92.0% | Buy | +256.3% | Assigned | 04.09.26on TipRanks Sep 3 16:30 | +0.6%next day −1.7% · 5 days −7.4% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $40.00 | Buy | +197.0% | Reiterated | 13.08.26on TipRanks 11:35 | +1.9%next day +4.0% · 5 days −8.9% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $40.00 → $48.00+20.0% | Buy | +256.3% | Reiterated | 11.08.26on TipRanks 13:30 | +3.2%next day +3.6% · 5 days +5.8% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $45.00 → $47.00+4.4% | Buy | +248.9% | Reiterated | 11.08.26on TipRanks 07:55 | +3.2%next day +3.6% · 5 days +5.8% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $74.00 → $77.00+4.1% | Buy | +471.6% | Reiterated | 10.08.26on TipRanks Aug 11 07:10 | −1.0%next day +3.2% · 5 days +8.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 10.08.26on TipRanks Aug 11 02:35 | −1.0%next day +3.2% · 5 days +8.0% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $45.00 | Buy | +234.1% | Initiated | 15.06.26on TipRanks 05:40 | +3.2%next day −2.9% · 5 days +39.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Jade Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $50.50 at a price of $14.05 (+259.4%); now: $50.50 at $13.47 (+274.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 10 | 14 | 9 | 13 |
| Buy | 6 | 5 | 6 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.73 (from $-0.86 to $-0.57). Last quarter: $-0.76.
Best top-analyst consensus in the sector · Healthcare
About Jade Biosciences
- CEO: Tom Frohlich
- Employees: 55
- Building 23, Waltham, MA, 02453, US
- jadebiosciences.com
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 60 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗